ISSN 1214-0287 (on-line), ISSN 1214-021X (printed)
J Appl Biomed
Volume 8 (2010), No 2, p 81-86
DOI 10.2478/v10136-009-0012-x

The incidence of beta-defensin-1, 2, 3 in human healthy and chronically inflamed nasal and tonsillar mucosa

Hana Pacova, Jaromir Astl, Jindrich Martinek

Address: Hana Pacova, Inst. of Histology and Embryology, First Faculty of Medicine, Charles University, Albertov 4, 128 01 Prague 2, Czech Republic

Received 26th August 2009.
Published online 23rd March 2010.

Full text article (pdf)
Full text article (html)
Abstract in xml format

The nasal and tonsillar mucosa are exposed to massive incursions of pathological microorganisms. One of the mechanisms known to prevent an invasion of pathogens is an endogenous synthesis of antimicrobial peptides, which include human beta-defensins-1, 2, 3 (HBD-1, 2, 3).
The aim of this study was to demonstrate the occurrence of HBD-1, 2 and 3 in the human nasal mucosa and palatine tonsils in healthy tissues and during chronic inflammation (nasal polyposis with and without the colonization of Staphylococcus aureus and chronic tonsillitis) and to evaluate their incidence under varying conditions.
Another target was to compare the occurrence of human beta-defensins in these two different entities; that is, in the nasal mucosa and in the palatine tonsil.
It was assumed that the incidence of HBD-1, 2, 3 was lower in tonsils than in nasal mucosa; however, inflamed samples of tonsils and nasal mucosa showed no difference in the production of HBD-1, 2, 3. The presence of all three subfamilies of HBD was significantly lower in nasal polyps with Staphylococcus aureus positive than in the negative control.

beta-defensins; nasal mucosa; palatine tonsil; chronic inflammation

Ball SL, Siou GP, Wilson JA, Howard A, Hirst BH, Hall J: Expression and immunolocalisation of antimicrobial peptides within human palatine tonsils. J Laryngol Otol 121:973-978, 2007.

Claeys S, de Belder T, Holtappels G, Gevaert P, Verhasselt B, van Cauwenberge P, Bachert C: Human beta-defensins and toll-like receptors in the upper airway. Allergy 58:748-753, 2003.

Cole AM, Tahk S, Oren A, Yoshioka D, Kim YH, Park A, Ganz T: Determinants of Staphylococcus aureus nasal carriage. Clin Diag Immunol 8:1064-1069, 2001.

Dunsche A, Acil Y, Siebert R, Harder J, Schroder JM, Jepsen S: Expression profile of human defensins and antimicrobial proteins in oral tissues. J Oral Pathol Med 30:154-158, 2001.

Harder J, Bartels J, Christophers E, Schroeder JM: A peptide antibiotic from human skin. Nature 387:861, 1997.

Kluver E, Adermann K, Schulz A: Synthesis and structure-activity relationship of beta-defensins, multi-functional peptides of the immune system. J Pept Sci 12:243-257, 2006.

Lee SH, Kim JE, Lim HH, Lee HM, Choi JO: Antimicrobial defensin peptides of the human nasal mucosa. Ann Otol Rhinol Laryngol 111:135-141, 2002.

Po-Hsu Ch, Sheen-Yie F: Expression of human beta-defensin 2 in human nasal mucosa. Eur Arch Otorhinolaryngol 216:238-241, 2004.

Quinn GA, Cole AM: Suppression of innate immunity by nasal carriage strain of Staphylococcus aureus increases its colonization on nasal epithelium. Immunology 122:80-89, 2007.

Schibli DJ, Hunter HN, Aeyev V, Starner TD, Wiencek JM, Mccray PB: The solution structures of human beta-defensin 3 lead to better understanding of the potent bactericidal activity of HBD-3 against Staphylococcus aureus. J Biol Chem 277:8279-8289, 2002.

Weise JB, Meyer JE, Helmer H, Wittrock H, Maune S: A newly discovered function of palatine tonsils in immune defence: the expression of defensins. Otolaryngol Pol 56:409-413, 2002.

Berger J. The age of biomedicine: current trends in traditional subjects. J Appl Biomed. 9: 57-61, 2011.